The $150 million gives Sanofi rights to develop its small molecule IRAK4 protein degraders in inflammation and immunology indications, and a second earlier stage undisclosed programme.

Sanofi has launched a new initiative in its drive to integrate digital technologies throughout its business, setting up an accelerator based in Paris that will serve as the lynchpin of the effort.

Sanofi Exercises License Extension Option to Nurix’s STAT6 Program. ... a Novel IRAK4 Degrader for Inflammatory Conditions. Collaboration partner, Gilead Sciences, ...